CTRI/2010/091/001353已完成1 期
Phase 1 human study for single dose combination of oral Alpha-ketoglutarate (5 grams and 15 grams) & Inj. Sodium Thiosulphate 12.5 grams i.v.
Defence R&D Organisation0 个研究点目标入组 26 人开始时间: 待定最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 26
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Healthy human volunteers 18 - 50 years of age with 50-70kg of body weight.
- •2. On no permanent treatment
- •3. Suffering from no permanent / recurrent / chronic disease or disability
- •1. Otherwise healthy human volunteers of 25 - 60 years of age with 50-70kg of body weight, half with history of mild to moderate essential hypertension (systolic blood pressure between 140-160 mm Hg at time of test), with or without treatment.
排除标准
- •1. Volunteers who do not sign the consent form.
- •2. Those with any contraindication for giving AKG/STS/SNP and those who are hypotensive
- •3. Patients with abnormalities in the laboratory screen (SGOP or SGPT > 1.5 times upper limit of normal, alkaline phosphates > 1.2 times upper limit of normal, serum creatinine> 1.5 mg/dl)
- •4. Patients who have any medical condition which in the judgment the investigator may render them inappropriate for participation in the trial
- •5. Patients who have received any other investigational drug for the last 1 month
- •6. Patients with smoking history of >10 pack-years
研究者
相似试验
尚未招募
不适用
A Phase I study to evaluate a single oral dose of SRT2379 on the endotoxin induced inflammatory response in healthy male subjectsDoor endotoxine veroorzaakte inflammatie reactieInflammationinnate immunesystem10002252NL-OMON36662Sirtris Pharmaceuticals, Inc.16
已完成
不适用
Phase I dose-escalation trial for the combination of sorafenib with interleukin-2 (IL-2) in patients with clear cell renal cancerNL-OMON30060KI-AV30
已完成
1 期
A study in healthy volunteers to investigate how the test medicine CORT113176 is taken up by the body when given with food and without foodAmyotrophic lateral sclerosis (ALS)Nervous System DiseasesMotor neuron diseaseISRCTN52169163Corcept Therapeutics (United States)35
已完成
不适用
A single dose clinical trial to study the safety of ART-I02 in patients with arthritisarthritis10003816NL-OMON45686Arthrogen B.V.12
撤回
不适用
A single dose clinical trial to study the safety of ART-I02 in patients with rheumatoid arthritis10003816rheumatoid arthritisNL-OMON43315Arthrogen B.V.15
